CD56 is a natural killer (NK) cell marker that has been identified in approximately 15–20% of
acute myeloid leukemia (AML) cases, where it has been associated with monocytic …

Expression of CD56, a marker of natural killer (NK) cells, in acute lymphocytic leukemia
(ALL) is rare and, to date, has been described only in non‐B lineage ALL. Among 194 …

Background and Purpose: CD56 is a marker of natural killer cells, but can also be found on
blast cells in acute myeloid leukemia (AML). The prognostic implications of CD56 …

CD7/CD56 myeloid/natural killer acute leukemia represents a novel rare distinct
hematologic neoplasia. 1 According to its immunologic markers, it is classified as an acute …

The CD56 antigen is normally expressed on natural-killer cells but has additionally been
shown to be present on a variety of hematologic malignancies, including a subset of acute …

Some cases of T‐cell acute lymphoblastic leukaemia (ALL) express markers found in natural‐
killer (NK) cells, such as CD56 and CD16. Out of 84 T‐cell ALL cases diagnosed at our …

In hematological neoplasms CD56 (N-CAM) is expressed by T/natural killer (NK) cell
lymphoma, by most neoplastic plasma cells in multiple myeloma and also in a subset of …

A number of clinical and biological factors in acute myeloid leukemia (AML) have been used
to predict the response to induction treatment or the likelihood of relapse …

The prognostic significance of selected markers of leukemic cells is well known. CD7 and
CD56 expression at diagnosis has been associated with low remission rates and biological …

The diversity of clinical, hematological and genetic features among patients with acute
myeloid leukemia (AML) has been recognized for many decades. However, during recent …